

Synthesis of Interleukin 1 β , Tumor Necrosis Factor- α , and Interstitial Collagenase (MMP-1) Is Eicosanoid Dependent in Human Osteoarthritis Synovial Membrane Explants: Interactions with Antiinflammatory Cytokines

WENDY HE, JEAN-PIERRE PELLETIER, JOHANNE MARTEL-PELLETIER, STEFAN LAUFER, and JOHN A. DI BATTISTA

ABSTRACT. *Objective.* To determine the level of leukotriene B₄ (LTB₄) synthesized and released by synovium of patients with osteoarthritis (OA), and to study the role of lipoxygenase (LO)/cyclooxygenase (COX) products on proinflammatory cytokine and interstitial collagenase (MMP-1) synthesis.

Methods. Human OA synovial explants were cultured in the presence of lipopolysaccharide (L) and the ionophores ionomycin (I) and thapsigargin (T) (LIT) for 72 h at 37°C, and LTB₄ released into the culture medium was measured in the absence or presence of a COX-2-specific inhibitor, NS-398, or the 5-LO activating protein inhibitor Bay-x-1005. Increasing concentrations of LTB₄ (10⁻⁹ to 10⁻⁶ M) were incubated with explants for 24 h at 37°C, and interleukin 1 β (IL-1 β) and tumor necrosis factor- α (TNF- α) in the conditioned medium were quantitated by ELISA. The effect of endogenous eicosanoids on basal and induced levels of IL-1 β , TNF- α , and MMP-1 synthesis was examined by incubating explants in the presence of NS-398 and Bay-x-1005. The effect of antiinflammatory cytokines rhIL-4, IL-10, and IL-13 on basal and LTB₄ dependent stimulation of IL-1 β /TNF- α synthesis was studied under titration conditions.

Results. Physiologically relevant concentrations (10⁻¹⁰ to 10⁻⁹ mol/l) of LTB₄ were produced in the presence of LIT. Bay-x-1005 abrogated LTB₄ release, while NS-398 was without effect. LTB₄ stimulated IL-1 β and TNF- α synthesis with an EC₅₀ of 190 \pm 35 and 45 \pm 9 nmol/l, respectively. Significant concentrations of IL-1 β and TNF- α were released (100–200 and 500–600 pg/ml, respectively). Basal and LIT induced IL-1 β and TNF- α production were inhibited by Bay-x-1005 in a dose dependent manner, while the addition of NS-398 caused a potent stimulatory effect. The preferential COX-2 inhibitor also induced MMP-1 synthesis in a manner essentially identical to the proinflammatory cytokines. The antiinflammatory cytokine IL-4 blocked LTB₄ dependent stimulation of IL-1 β and TNF- α synthesis. In contrast, IL-10 markedly stimulated both cytokines when incubated alone or in the presence of LTB₄, where the effect was additive.

Conclusion. Endogenous and locally produced eicosanoids regulate proinflammatory cytokine and MMP-1 synthesis under basal and stimulated conditions *in vitro*, with leukotrienes and prostaglandins having opposite effects in general. The clinical use of antiinflammatory drugs that inhibit eicosanoid synthesis requires an appreciation of their relative capacity to inhibit LO/COX in order to predict their effect on the synthesis of proinflammatory cytokines and matrix metalloproteinases. IL-10 stimulated proinflammatory cytokine synthesis in our *ex vivo* culture system. (J Rheumatol 2002;29:546–53)

Key Indexing Terms:

COLLAGENASE
LEUKOTRIENE

EICOSANOID

OSTEOARTHRITIS
INFLAMMATION

From the Osteoarthritis Research Unit, Hôpital Notre-Dame, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada; and Eberhard-Karls-University, Tübingen, Germany.

Supported in part by the Arthritis Society, the Canadian Institute of Health Research, and Merckle GmbH, Ulm, Germany.

W. He, MD; J.-P. Pelletier, MD; J. Martel-Pelletier, PhD; J.A. Di Battista, PhD, Centre Hospitalier de l'Université de Montréal; S. Lauffer, PhD, Eberhard-Karls-University.

Address reprint requests to Dr. J.A. Di Battista, Unité de recherche en Arthrose, Hôpital Notre-Dame, Centre hospitalier de l'Université de Montréal, 1560 rue Sherbrooke est, Montréal, Québec, Canada H2L 4M1. E-mail: dibattista@sympatico.ca

Submitted June 19, 2001; revision accepted September 28, 2001.

Osteoarthritis (OA) is the most common of the rheumatic diseases and it is idiopathic, notwithstanding the compelling evidence that distinct forms of OA are inherited as dominant Mendelian traits¹. Increased cartilage degradation and secondary synovitis are key events in the pathogenesis of the disease, and it appears that the synovitis is fundamental to the appearance and progression of cartilage lesions^{1,2}. In part, this is due to the secretion of proinflammatory mediators that increase cartilage catabolism. Prototypic among these factors are interleukin 1 β (IL-1 β) and tumor necrosis factor- α (TNF- α), which are present and elaborated in OA

joint tissues. These cytokines have been shown to suppress the synthesis of cartilage matrix macromolecules while stimulating that of extracellular matrix destructive metalloproteases (MMP) (e.g., MMP-1, MMP-2, MMP-3, MMP-8, MMP-9, MMP-13)^{3,4}. In addition, they stimulate the synthesis and release of lipid mediators, derived from cyclooxygenase (COX) and lipoxygenase (LO) metabolism of arachidonic acid, that are etiologically associated with arthritic and inflammatory diseases⁵. Indeed, increased levels of prostaglandins (PG) and leukotrienes (LT) have been detected in synovial tissue and fluid in OA and rheumatoid arthritis (RA)^{6,7}, likely released by infiltrating monocyte/macrophages, mast cells, neutrophils, and human polymorphonuclear leukocytes (PMN). Proof of this exists in studies describing the antirheumatic and antiinflammatory properties of drugs (nonsteroidal antiinflammatory drugs, NSAID) that block COX/LO activity^{8,9}. Recent studies in animal models and clinical trials have convincingly shown the potential of drugs that inhibit LO derived LT in the treatment of rheumatic diseases¹⁰⁻¹³. Presumably, by reducing production of eicosanoids and LT, which are known to function in an intracrine, paracrine, and autocrine fashion, leukocyte infiltration, vasodilatation, chemotaxis, pyresis, thrombosis, bronchoconstriction, and platelet aggregation will be inhibited^{14,15}. What has not been fully established is the mechanistic rationale at the cellular and molecular level for the therapeutic efficacy of these classes of medications. Recent studies have indicated that LT, acting through positive feedback loops, increase the synthesis of IL-1 in explants of human synovial tissue^{10,16}. Further, we have recently shown that LTB₄ upregulates COX-2 expression through both transcriptional activation and posttranscriptional message stabilization¹⁷. Stimulation of the nuclear factor- κ B (NF- κ B) signaling cascade by LTB₄ has been documented and is likely responsible for mediating the LTB₄ dependent transcriptional effects on COX-2 and IL-1¹⁸⁻²⁰.

In terms of the development and resolution of inflammation, relatively little is known about the interrelationship between the so-called antiinflammatory cytokines (e.g., IL-4, IL-10, IL-13), proinflammatory cytokines, and the LO system. Recent evidence has shown significant quantities of IL-4 and IL-10 in OA and RA synovia produced by infiltrating T cells^{21,22}. In some studies^{23,24}, the Th2 cell derived cytokines stimulated LTB₄ synthesis and release from PMN and macrophages through the activation of LTB₄ hydroxylase and/or 5-LO. Conversely, in isolated ionophore activated monocyte/macrophages, there was a general inhibitory effect by IL-4 and IL-13 on LTB₄ release induced by IL-1 or interferon- γ ²⁵. Further, IL-4 and IL-10 were shown to inhibit IL-1 β synthesis by freshly released adherent rheumatoid synovial cells²⁶, while IL-13 suppressed IL-1 β and TNF- α expression and synthesis in OA synovium²⁷.

We examined the effects of exogenously added

(paracrine) and endogenous levels (intra/autocrine activity) of LTB₄ and PGE₂ on IL-1 β , TNF- α , and MMP-1 synthesis/release by OA synovial explants. Further, we investigated whether IL-4, IL-10, and IL-13 can mitigate LTB₄ action and cell signaling by studying their effects on LTB₄ induced IL-1 β /TNF- α synthesis by OA synovium.

MATERIALS AND METHODS

Chemicals. Bay-x-1005 was kindly provided by Merckle GmbH (Ulm, Germany). NS-398, N-[2-(cyclohexyloxy)-4-nitrophenyl]-methanesulfonamide, PGE₂, and LTB₄ were purchased from Cayman Chemical (Ann Arbor, MI, USA). Lipopolysaccharide (LPS), ionomycin, thapsigargin, 3-isobutyl-1-methylxanthine (IBMX), and forskolin were products of Calbiochem (La Jolla, CA, USA). Human recombinant IL-1 β (rhIL-1 β), rhIL-4, rhIL-10, rhIL-13, and rhTNF- α were purchased from R&D Systems (Minneapolis, MN, USA). HEPES buffered Dulbecco's modified Eagle medium (HB-DMEM), heat inactivated fetal bovine serum (FBS), and an antibiotic mixture (10,000 units of penicillin G sodium, 10,000 μ g of streptomycin sulfate), and DNAzol reagent were products of Gibco BRL-Life Technologies (Burlington, Ontario, Canada).

Specimen selection and synovial fibroblast cultures. Synovial membranes were obtained from OA patients undergoing arthroplasty of the knee who had been diagnosed based on the American College of Rheumatology criteria²⁸ (mean age 67 \pm 19 yrs; M/F 1:3). Each OA synovium was aseptically dissected completely free from underlying fibrous and adipose tissue under a dissecting microscope; samples were rejected if the latter requirement could not be satisfied. Explant samples were weighed aseptically to 300 \pm 50 mg, divided randomly into experimental groups, and incubated 24–36 h (washout period) in explant culture medium [HB-DMEM + 10% FBS + Pen-Strep (100 U/100 μ g)] at 37°C in a humidified atmosphere containing 5% CO₂/95% air prior to experiments. After experimentation, explants were extracted for genomic DNA using the DNAzol reagent per manufacturer's instructions (Gibco-BRL) and values were used to verify tissue weights.

Eicosanoid ELISA. Measurements of PGE₂, LTB₄, MMP-1, IL-1 β and TNF- α in conditioned medium were by ELISA according to the manufacturer's instructions (R&D Systems). Detection limits for PGE₂ and LTB₄ were 39 and 3.9 pg/ml, respectively, 21 pg/ml for pro-MMP-1, while limits for IL-1 β and TNF- α were 1 and 4.4 pg/ml, respectively. ELISA for pro-MMP-1 was specific for the free zymogen only.

Statistical analysis. Values were expressed as mean \pm SD and mean differences between experimental groups were analyzed by 2 tailed paired Student t test or where appropriate by ANOVA with post-hoc Bonferroni multiple comparison tests. Significance was acknowledged with probability < 5%.

RESULTS

Release of LTB₄ by synovial explants. Nine of 22 explant cultures spontaneously released small quantities of LTB₄ (roughly 15 pg/g tissue wet weight) in culture under our incubation conditions. However, when activated with LPS and particularly with LPS in the presence of calcium flux stimulators ionomycin (10 nmol/l) and thapsigargin (20 nmol/l) (LIT), far larger amounts of LTB₄ were produced (120–150 pg/g tissue wet weight, n = 4) (Figure 1). Cyclic AMP (cAMP) mimetics also increase induced LTB₄ production, but were less efficient than the stimulators of calcium flux. When incubated alone, ionophore and cAMP mimetic-stimulated levels of LTB₄ production were modestly but significantly different from controls. The 5-LO activating




Figure 1. Release of LTB₄ by human synovial explants in culture. Explants were stimulated 72 h at 37°C in the absence (control) or presence of forskolin (FK, 60 μmol/l) and IBMX (100 μmol/l), ionomycin (Iono, 10 nmol/l), and thapsigargin (Thap, 20 nmol/l), or with LPS (20 μg/ml). Coincubations consisted of LPS and IBMX + FK or Iono + Thap with or without Bay-x-1005 (1 μmol/l) or NS-398 (1 μmol/l). Concentration of LTB₄ in the conditioned medium was measured by ELISA. Statistical analysis by 2 tailed Student t test compared to control.

protein (FLAP) inhibitor Bay-x-1005 blocked LIT-induced LTB₄ release by 83.79 ± 4.57% (mean ± SD) at 1 μmol/l, while at the same concentration NS-398, a preferential COX-2 inhibitor, had no effect in this regard.

Effects of LTB₄ on proinflammatory cytokine production.

Given the production of LTB₄ from OA synovium, we performed the following experiments to examine whether LTB₄ could induce production of the major proinflammatory cytokines IL-1β and TNF-α. Exogenously added LTB₄ stimulated the release of IL-1β and TNF-α in a concentration-dependent fashion with an EC₅₀ of 190 ± 35 nmol/l and 45 ± 9 nmol/l (n = 6), respectively (Figures 2A, 2B). Under these conditions, pathophysiologically relevant concentrations of IL-1β and TNF-α were released (100–200 and 500–600 pg/ml, respectively). LPS (20 μg/ml) was added as positive control and stimulated both cytokines potently, 395 ± 65 pg/ml of IL-1β and 4500 ± 895 pg/ml of TNF-α (n = 6; Figures 2A, 2B).

To address the effect of endogenously produced eicosanoids on cytokine production, Bay-x-1005 was added in increasing concentrations and caused a decrease in basal levels of IL-1β and TNF-α by a maximum of 39.95 ± 14.66% and 46.79 ± 13.8% (n = 4), respectively, at 1 μmol/l (Figure 3A). In contrast, NS-398, a preferential COX-2 inhibitor, stimulated the release of both IL-1β (maximum 372.6 ± 127.19%, n = 4) and TNF-α (maximum 198.57 ± 12.12%, n = 4) over controls at therapeutically relevant




Figure 2. Dose dependent stimulation of IL-1β and TNF-α release by LTB₄ in human synovial explants in culture. Explants were stimulated 24 h at 37°C in the absence or presence of increasing concentrations of LTB₄ (10⁻⁹ to 10⁻⁶ mol/l) or LPS (20 μg/ml) as a positive control. Levels of IL-1β (A) and TNF-α (B) were measured in the conditioned medium by ELISA. ANOVA (A) F = 369.49, p < 0.0001; F = 880.89, p < 0.0001, excluding LPS.

concentrations (0.01 to 1 μmol/l) (Figure 3B). In these experiments, basal release of IL-1β and TNF-α varied between 14.9 and 34.5 pg/300 mg wet weight. When the membrane explants were exposed to LIT stimulation, Bay-x-1005 inhibited IL-1β (maximum 54.28 ± 8.38%, n = 4)




Figure 3. Role of endogenous production of LTB_4 and PGE_2 on IL-1 β , TNF- α , and MMP-1 release in human synovial explants in culture. Explants were incubated 24 h at 37°C under basal (A, B) or LIT [LPS (20 $\mu\text{g}/\text{ml}$), ionomycin (10 nmol/l), thapsigargin (20 nmol/l)] (C, D, E) stimulatory conditions in the absence or presence of increasing concentrations (A, C) of Bay-x-1005 (0.01, 0.1, 1, 10 $\mu\text{mol}/\text{l}$ or 0.0036, 0.036, 0.36, 3.6 $\mu\text{g}/\text{ml}$) or (B, D, E) NS-398 (0.01, 0.1, 1, 10 $\mu\text{mol}/\text{l}$ or 0.0031, 0.031, 0.31, 31 $\mu\text{g}/\text{ml}$). The concentrations of IL-1 β , TNF- α , and MMP-1 were measured in conditioned medium by ELISA. Statistical analysis, ANOVA and Bonferroni post-hoc test (A) IL-1 β , $F = 11.94$, $p = 0.0001$; control vs 0.01 $\mu\text{mol}/\text{l}$ Bay-x-1005, not significant (NS); TNF- α , $F = 10.98$, $p = 0.0002$; control vs 0.01 $\mu\text{mol}/\text{l}$ Bay-x-1005, NS; (B) IL-1 β , $F = 23.24$, $p < 0.0001$; control vs 10 $\mu\text{mol}/\text{l}$ NS-398, NS; TNF- α , $F = 29.04$, $p < 0.0001$; control vs 10 $\mu\text{mol}/\text{l}$ NS-398, NS; (C) IL-1 β , $F = 31.41$, $p < 0.0001$; control vs 0.01 $\mu\text{mol}/\text{l}$ Bay-x-1005, NS; TNF- α , $F = 29.45$, $p < 0.0001$; control vs 0.01 $\mu\text{mol}/\text{l}$ Bay-x-1005, NS; (D) IL-1 β , $F = 27.25$, $p < 0.0001$; control vs 10 $\mu\text{mol}/\text{l}$ NS-398, NS; TNF- α , $F = 14.47$, $p < 0.0001$; control vs 10 $\mu\text{mol}/\text{l}$ NS-398, NS; (E) $F = 11.13$, $p < 0.0001$ [overleaf].




Figure 3E.

and TNF- α (maximum $51.56 \pm 6.99\%$, $n = 4$) release, while NS-398 stimulated IL-1 β (maximum $411.93 \pm 66.46\%$, $n = 4$) and in particular TNF- α (maximum $295.4 \pm 92.55\%$, $n = 4$) release, as illustrated in Figures 3C and 3D. The nonselective COX inhibitor naproxen had stimulatory effects similar to NS-398 (data not shown). In the presence of LIT, values were between 1850 and 6300 pg/300 mg wet weight for IL-1 β and 3300–9650 pg/300 mg wet weight for TNF- α . Interestingly, NS-398 stimulated proMMP-1 release from LIT activated membrane explants, reaching a zenith of $191 \pm 41.5\%$ ($n = 7$) at 0.1 μmol (Figure 3E); Bay-x-1005 had no effect in this regard (data not shown). With respect to MMP-1, nonstimulated tissue released between 58 and 587 ng/300 mg wet weight, while in the presence of LIT we obtained between 110 and 905 ng/300 mg wet weight.

In companion measurements using the same culture medium, basal concentrations of PGE₂ were totally unaffected by Bay-x-1005 (control, $17,298 \pm 1218$ vs 10 $\mu\text{mol/l}$ of Bay-x-1005, $17,460 \pm 1634$ pg PGE₂/100 mg tissue wet weight, $n = 4$). As expected, NS-398 inhibited basal PGE₂ production (control, $17,298 \pm 1218$ vs 1 $\mu\text{mol/l}$ of NS-398, 536 ± 101 pg PGE₂/100 mg tissue wet weight, $n = 4$). The IC₅₀ for Bay-x-1005 suppression of LIT stimulated LTB₄ production was 0.33 ± 0.21 $\mu\text{mol/l}$ ($n = 4$); V_{max} of the reaction was 147 ± 39 pg LTB₄/g tissue wet weight. The IC₅₀ for NS-398 suppression of LIT stimulated PGE₂ production was 12.2 ± 3.6 nmol/l ($n = 4$); the total amount of PGE₂ released in the presence of LIT was 6.89 ± 0.35 $\mu\text{g}/100$ mg tissue wet weight, while the addition of 0.01, 0.1, 1.0, and 10.0 $\mu\text{mol/l}$ of NS-398 reduced this amount to 4.01 ± 0.21 , 0.25 ± 0.04 , 0.02 ± 0.01 , and 0.0189 ± 0.007 $\mu\text{g}/100$ mg tissue wet weight, respectively ($n = 4$).

Pro and antiinflammatory cytokine interactions in LTB₄ treated human OA synovial explants. The antiinflammatory T cell derived cytokine IL-4 reversed the stimulatory effect of LTB₄, in terms of both IL-1 β and TNF- α , in a concentration dependent fashion with a maximum inhibition of 83% at 10 ng/ml (Figures 4A, 4B); IL-4 had no significant effect on basal levels of these 2 cytokines. In contrast, IL-10 at 100 pg/ml stimulated IL-1 β and TNF- α release and, when coincubated with LTB₄, did so in a concentration dependent manner (Figures 4A, 4B). IL-13 also modestly reversed the LTB₄ stimulatory pattern at lower concentrations, while at 10 ng/ml the cytokine produced an additive effect with LTB₄ (data not shown).

DISCUSSION

The involvement of lipoxygenase products in the pathophysiology of OA has been implied from studies using experimental OA and animal models. Leukotriene B₄ was detected in significant quantities in the synovial fluid and joint tissues of untreated control animals, and treatments with chemical inhibitors of LO, FLAP, and/or LTA₄ hydrolyase were shown to inhibit the severity of the disease^{15,29}. Validation of the concept has also come from studies with OA patients where the presence of LTB₄ in synovial fluid was conspicuous and 5-LO inhibitors proved efficacious in remediating disease symptomology^{10,13,30}. This study shows that human OA synovial explants have the capacity to produce significant quantities of LTB₄ when the tissue is treated with calcium ionophores, confirming previous studies^{5,10,31}. Cells derived from synovial tissue express 5-LO and FLAP mRNA and 5-LO metabolites were detected in the conditioned culture medium³². It should be remembered that the OA synovium is replete with proliferating type A and B synoviocytes, and in the subintimal layer macrophages, mast cells, plasma cells, T and B lymphocytes, endothelial cells (blood vessels), and neutrophils may be present. To a degree, these changes may likely be the manifestation of LTB₄ induced chemotaxis of blood-borne and synovial fluid neutrophils that will degranulate and release destructive lysosomal enzymes. Also, LTB₄ can affect leukocyte adhesion to capillary walls, thus cell trafficking is affected to the point where cells may no longer migrate^{11,14,33}.

The LTB₄ detected in our culture supernatants was inhibited by the FLAP inhibitor Bay-x-1005 but was refractory to NS-398, a preferential COX-2 inhibitor. Previous studies measured calcium ionophore (A23187) activated LTB₄ release from synovial explants^{10,31}; however, we found a synergistic relationship between mixed ionophores (ionomycin/thapsigargin) and LPS that gave much more stimulation than ionophores alone. It is now well established that increases in cellular calcium favor the translocation of 5-LO from cytoplasmic stores to its membrane docking protein (FLAP), where it can then interact with its substrate, arachi-




Figure 4. Regulation of IL-1 β (A) and TNF- α (B) synthesis by antiinflammatory cytokines in LTB $_4$ treated human synovial explants. Explants were incubated 24 h at 37°C in the absence (control, C) or presence of LTB $_4$ (190 nmol/l for A and 45 nmol/l for B), rhIL-4 (100 pg/ml), rhIL-10 (100 pg/ml), or LTB $_4$ in the presence of increasing concentrations of rhIL-4 (1–10,000 pg/ml) or rhIL-10 (1–10,000 pg/ml). Concentrations of IL-1 β (A) and TNF- α (B) were measured in the conditioned medium by ELISA. (A) Student t test: $p < 0.0001$ and $p < 0.008$ vs control; ANOVA: LTB $_4$, LTB $_4$ + rhIL-10 (1–10,000 pg/ml), $F = 50.58$, $p < 0.0001$, Bonferroni post-hoc tests, LTB $_4$ vs LTB $_4$ + rhIL-10 (1–100 pg/ml), NS; LTB $_4$, LTB $_4$ + rhIL-4 (1–10,000 pg/ml), $F = 28.95$, $p < 0.0001$, Bonferroni, LTB $_4$ vs LTB $_4$ + rhIL-4 (1 pg/ml), NS; (B) $p < 0.001$ and $p < 0.0001$ vs control; ANOVA: LTB $_4$, LTB $_4$ + rhIL-10 (1–10,000 pg/ml), $F = 81.25$, $p < 0.0001$, Bonferroni post-hoc tests, LTB $_4$ vs LTB $_4$ + rhIL-10 (1, 10 pg/ml), NS. LTB $_4$, LTB $_4$ + rhIL-4 (1–10,000 pg/ml), $F = 98.5$, $p < 0.0001$.

donic acid (AA). However, we reasoned that the addition of LPS would stimulate MAP kinase dependent phosphorylation of cytosolic phospholipase A $_2$ (cPLA $_2$), with the resultant increase in cellular levels of AA driving the forward reaction toward 5-LO/COX metabolites^{34–37}.

Further, 5-LO promoter activity, gene expression, and LTB $_4$ release are enhanced by substances that augment the transcriptional activity of early growth response factor (Egr-

1/Krox24), and cAMP mimetics (e.g., IBMX and forskolin) are known to do so^{38,39}. Parenthetically, inhibitors of cAMP formation block leukotriene synthesis and release in certain cell types³³. This cAMP dependent mechanism is not as productive as activation by calcium ionophores; however, it does provide another signaling paradigm by which leukotriene synthesis may be upregulated.

In addition to the well described proinflammatory effects of LTB $_4$ and leukotrienes in general, our data suggest that the cytokines IL-1 β and TNF- α are also under the control of locally produced LTB $_4$. The stimulation of IL-1 β synthesis by LTB $_4$ in synovial explants has been described^{10,16}, and we now also report a potent effect on TNF- α (IC $_{50}$ 45 nmol/l). This LTB $_4$ dependent effect was confirmed by blocking endogenous levels of LTB $_4$ with the FLAP inhibitor Bay-x-1005, resulting in downregulation of basal cytokine secretion. Under LPS stimulatory (inflammatory) conditions, the drug could reduce cytokine levels by about 45–50%, again implying a role for leukotrienes under simulated inflammatory conditions *in vitro* and confirming the notion that a significant portion of liberated AA is metabolized by the LO pathway in OA synovial membrane explants. However, more compelling are the present data showing just how important the COX pathway metabolites may be in the regulation of proinflammatory cytokine and MMP-1 release. NS-398 (and naproxen) stimulated the basal and induced release of both cytokines and MMP-1 in a very pronounced fashion, and it is tempting to conclude that prostaglandins, particularly PGE $_2$, function as a homeostatic bioregulator in both nonpathological and pathological (OA) conditions. Our results support our previous experiments and those of others that showed the inhibitory effects of exogenous and endogenous PGE $_2$ on TNF- α expression and synthesis and IL-1 β maturation and release in isolated human macrophages^{40–43}. The concomitant coordinated synthesis of IL-1 β /TNF- α and MMP-1 in the face of COX-2 inhibition provides further support for a strong relationship between proinflammatory cytokines and matrix destructive metalloproteases in the pathophysiology of OA^{44–46}.

The most successful gene therapy approaches for treating experimental OA make use of gene transfer technology that codes for proteins that block proinflammatory cytokine activity⁴⁷. Examples would be genes coding for IL-1 receptor antagonist (IL-1RA) and soluble receptors for TNF- α and IL-1 β . Furthermore, delivery and expression of genes encoding transforming growth factor- β , IL-4, IL-10, and IL-13 have also been shown to be effective particularly in RA models. The effectiveness of these so-called “anti-inflammatory” cytokines derives from their potent inhibition of lipid inflammatory mediators and proinflammatory cytokine synthesis^{27,48–51}. Nevertheless, there are conflicting reports about the effects of IL-4, IL-10, and IL-13 on LTB $_4$ release and their efficacy in blocking TNF- α /IL-1 β production, as noted. Our data confirm the inhibitory effects of IL-

4 on proinflammatory cytokine synthesis but clearly indicate that IL-10, particularly in the presence of LTB₄, is a potent activator in this regard. Couple the latter findings to the fact that IL-10 has been shown to increase the number of TNF- α cell surface receptors on macrophages isolated from OA synovial membranes and fluid⁵², and one may question the strategy of using IL-10 as an antirheumatic treatment.

There is now wide agreement that proinflammatory cytokines, particularly IL-1 β and TNF- α , play a cardinal role in the pathophysiology of arthritic diseases. Endogenous and ambient leukotrienes are powerful stimulators of proinflammatory cytokine synthesis and may occupy a prominent place in the hierarchy of mediators implicated in the inflammatory cascade. The development of pharmacological agents that inhibit leukotriene synthesis could thus be useful to treat OA and inflammatory arthritic conditions.

ACKNOWLEDGMENT

The authors thank Dr. Susanne Tries, Dr. Hans-Günter Striegel, and the technical staff of Merckle GmbH for the generous gift of Bay-x-1005.

REFERENCES

1. Pelletier JP, Martel-Pelletier J, Howell DS. Etiopathogenesis of osteoarthritis. In: Koopman WJ, editor. Arthritis and allied conditions. A textbook of rheumatology. 14th ed. Baltimore: Williams & Wilkins; 2000:2195-245.
2. Recklies AD, Poole AR, Banerjee S, et al. Pathophysiologic aspects of inflammation in diarthroidal joints. In: Buckwalter JA, Einhorn TA, Simon SR, editors. Orthopaedic basic science: biology and biomechanics of the musculoskeletal system. Rosemont, IL: American Academy of Orthopaedic Surgeons; 2000:489-530.
3. Pelletier JP, Di Battista JA, Roughley PJ, McCollum R, Martel-Pelletier J. Cytokines and inflammation in cartilage degradation. In: Moskowitz RW, editor. Osteoarthritis. Edition of Rheumatic Disease Clinics of North America. Philadelphia: W.B. Saunders Company; 1993:545-68.
4. Martel-Pelletier J, Di Battista JA, Lajeunesse D. Biochemical factors in joint articular tissue degradation in osteoarthritis. In: Reginster JY, Pelletier JP, Martel-Pelletier J, Henrotin Y, editors. Osteoarthritis: clinical and experimental aspects. Berlin: Springer-Verlag; 1999:156-87.
5. Ford-Hutchinson AW, Gresser M, Young RN. 5-Lipoxygenase. *Annu Rev Biochem* 1994;63:383-417.
6. Wittenberg RH, Willburger RE, Kleemeyer KS, Peskar BA. *In vitro* release of prostaglandins and leukotrienes from synovial tissue, cartilage, and bone in degenerative joint diseases. *Arthritis Rheum* 1993;36:1444-50.
7. Moilanen E, Alanko J, Nissila M, Hamalainen M, Isomaki H, Vapaatalo H. Eicosanoid production in rheumatoid synovitis. *Agents Actions* 1989;28:290-7.
8. Cashman JN. The mechanisms of action of NSAIDs in analgesia. *Drugs* 1996;52 Suppl 5:13-23.
9. Husni E, Simon LS. NSAID therapy: current concepts. In: Tsokos GC, Moreland LW, Kammer GM, Pelletier JP, Martel-Pelletier J, Gay S, editors. Modern therapeutics in rheumatic diseases. Totowa, NJ: Humana Press; 2002:47-64.
10. Rainsford KD, Ying C, Smith F. Effects of 5-lipoxygenase inhibitors on interleukin production by human synovial tissues in organ culture: comparison with interleukin-1-synthesis inhibitors. *J Pharm Pharmacol* 1996;48:46-52.
11. Musser JH, Kreft AF. 5-lipoxygenase: properties, pharmacology, and the quinolonyl(bridged)aryl class of inhibitors. *J Med Chem* 1992;35:2501-24.
12. Laufer SA, Augustin J, Dannhardt G, Kiefer W. (6,7-Diaryldihydropyrrolizin-5-yl) acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase. *J Med Chem* 1994;37:1894-7.
13. Laufer S, Tries S, Augustin J, Dannhardt G. Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase. *Arzneimittelforschung* 1994;44:629-36.
14. Borgeat P, Naccache PH. Biosynthesis and biological activity of leukotriene B₄. *Clin Biochem* 1990;23:459-68.
15. Tsuji F, Oki K, Fujisawa K, Okahara A, Horiuchi M, Mita S. Involvement of leukotriene B₄ in arthritis models. *Life Sci* 1999;64:PL51-6.
16. Kageyama Y, Koide Y, Miyamoto S, Yoshida TO, Inoue T. Leukotriene B₄-induced interleukin-1 β in synovial cells from patients with rheumatoid arthritis. *Scand J Rheumatol* 1994; 23:148-50.
17. Faour W, He Y, de Ladurantaye M, et al. Prostaglandin E₂ regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1 β treated synovial fibroblasts. *J Biol Chem* 2001;276:31720-31.
18. Los M, Schenk H, Hexel K, Baeuerle PA, Droge W, Schulze-Osthoff K. IL-2 gene expression and NF-kappa B activation through CD28 requires reactive oxygen production by 5-lipoxygenase. *EMBO J* 1995;14:3731-40.
19. Cogswell JP, Godlevski MM, Wisely GB, et al. NF-kappa B regulates IL-1 beta transcription through a consensus NF-kappa B binding site and a nonconsensus CRE-like site. *J Immunol* 1994;153:712-23.
20. Crofford LJ, Tan B, McCarthy CJ, Hla T. Involvement of nuclear factor kappa B in the regulation of cyclooxygenase-2 expression by interleukin-1 in rheumatoid synoviocytes. *Arthritis Rheum* 1997;40:226-36.
21. Canete JD, Martinez SE, Farres J, et al. Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. *Ann Rheum Dis* 2000;59:263-8.
22. Wagner S, Fritz P, Einsele H, Sell S, Saal JG. Evaluation of synovial cytokine patterns in rheumatoid arthritis and osteoarthritis by quantitative reverse transcription polymerase chain reaction. *Rheumatol Int* 1997;16:191-6.
23. Zaitu M, Hamasaki Y, Matsuo M, et al. New induction of leukotriene A(4) hydrolase by interleukin-4 and interleukin-13 in human polymorphonuclear leukocytes. *Blood* 2000;96:601-9.
24. Dugas N, Dugas B, Kolb JP, Yamaoka K, Delfraiss JF, Damais C. Role of leukotriene B₄ in the interleukin-4-induced human mononuclear phagocyte activation. *Immunology* 1996;88:384-8.
25. Nassar GM, Montero A, Fukunaga M, Badr KF. Contrasting effects of proinflammatory and T-helper lymphocyte subset-2 cytokines on the 5-lipoxygenase pathway in monocytes. *Kidney Int* 1997;51:1520-8.
26. Sugiyama E, Kuroda A, Taki H, et al. Interleukin 10 cooperates with interleukin 4 to suppress inflammatory cytokine production by freshly prepared adherent rheumatoid synovial cells. *J Rheumatol* 1995;22:2020-6.
27. Jovanovic D, Pelletier JP, Alaeddine N, et al. Effect of IL-13 on cytokines, cytokine receptors and inhibitors on human osteoarthritic synovium and synovial fibroblasts. *Osteoarthritis Cartilage* 1998;6:40-9.
28. Altman RD, Asch E, Bloch DA, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. *Arthritis Rheum* 1986;29:1039-49.
29. Hansen ES, Fogh K, Hjortdal VE, et al. Synovitis reduced by

- inhibition of leukotriene B₄. Carrageenan-induced gonarthrosis studied in dogs. *Acta Orthop Scand* 1990;61:207-12.
30. Atik OS. Leukotriene B₄ and prostaglandin E₂-like activity in synovial fluid in osteoarthritis. *Prostaglandins Leukot Essent Fatty Acids* 1990;39:253-4.
 31. Carty TJ, Sweeney FJ, Griffiths RJ, et al. Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal models. *Inflamm Res* 1997;46:168-79.
 32. Bonnet C, Bertin P, Cook-Moreau J, Chable-Rabinovitch H, Treves R, Rigaud M. Lipoxygenase products and expression of 5-lipoxygenase and 5-lipoxygenase-activating protein in human cultured synovial cells. *Prostaglandins* 1995;50:127-35.
 33. Ford-Hutchinson AW. Leukotriene B₄ in inflammation. *Crit Rev Immunol* 1990;10:1-12.
 34. Dennis EA. The growing phospholipase A₂ superfamily of signal transduction enzymes. *Trends Biochem Sci* 1997;22:1-2.
 35. Lin LL, Lin AY, DeWitt DL. Interleukin-1 α induces the accumulation of cytosolic phospholipase A₂ and the release of prostaglandin E₂ in human fibroblasts. *J Biol Chem* 1992;267:23451-4.
 36. Zhang FX, Kirschning CJ, Mancinelli R, et al. Bacterial lipopolysaccharide activates nuclear factor-kappa B through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. *J Biol Chem* 1999;274:7611-4.
 37. Muzio M, Natoli G, Saccani S, Levrero M, Mantovani A. The human toll signaling pathway: divergence of nuclear factor kappa B and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). *J Exp Med* 1998;187:2097-101.
 38. Gashler A, Sukhatme VP. Early growth response protein 1 (Egr-1): prototype of a zinc-finger family of transcription factors. *Prog Nucleic Acid Res Mol Biol* 1995;50:191-224.
 39. Silverman ES, Du J, Williams AJ, Wadgaonkar R, Drazen JM, Collins T. cAMP-response-element-binding-protein-binding protein (CBP) and p300 are transcriptional co-activators of early growth response factor-1 (Egr-1). *Biochem J* 1998;336:183-9.
 40. Di Battista JA, Martel-Pelletier J, Pelletier J. Suppression of tumor necrosis factor gene expression by prostaglandin E₂. Role of early growth response protein-1. *Osteoarthritis Cartilage* 1999;7:395-8.
 41. Di Battista JA, Jovanovic DV, He Y, Morin N, Martel-Pelletier J, Pelletier JP. Regulation of basal and lymphokine-induced IL-1 β and TNF- α gene expression by prostaglandin E₂ in human monocyte/macrophages. Elucidation of post-receptor signaling pathways [abstract]. *Arthritis Rheum* 1999;42 Suppl:S199.
 42. Seitz M, Loetscher P, Dewald B, Towbin H, Baggiolini M. In vitro modulation of cytokine, cytokine inhibitor, and prostaglandin E release from blood mononuclear cells and synovial fibroblasts by antirheumatic drugs. *J Rheumatol* 1997;24:1471-6.
 43. Caughey GE, Pouliot M, Cleland LG, James MJ. Regulation of tumor necrosis factor- α and IL-1 β synthesis by thromboxane A₂ in nonadherent human monocytes. *J Immunol* 1997;158:351-8.
 44. Takahashi S, Inoue T, Higaki M, Mizushima Y. Cyclooxygenase inhibitors enhance the production of tissue inhibitor-1 of metalloproteinases (TIMP-1) and pro-matrix metalloproteinase-1 (proMMP-1) in human rheumatoid synovial fibroblasts. *Inflamm Res* 1997;46:320-3.
 45. Zhang Y, McCluskey K, Fujii K, Wahl LM. Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF- α , granulocyte-macrophage CSF, and IL-1 β through prostaglandin-dependent and -independent mechanisms. *J Immunol* 1998;161:3071-6.
 46. Di Battista JA, Martel-Pelletier J, Kazushi I, Nagai Y, Zafarullah M, Pelletier JP. Prostaglandins E₂ and E₁ inhibit the cytokine-stimulated expression of metalloproteinases in normal human synovial fibroblasts: Mediation by cyclic AMP signalling pathway. *Lab Invest* 1994;71:270-8.
 47. Fernandes JC, Martel-Pelletier J, Pelletier JP. Gene therapy for osteoarthritis: new perspectives for the twenty-first century. *Clin Orthop* 2000;379 Suppl:S262-72.
 48. Raychaudhuri B, Fisher CJ, Farver CF, et al. Interleukin 10-mediated inhibition of inflammatory cytokine production by human alveolar macrophages. *Cytokine* 2000;12:1348-55.
 49. Deleuran B, Iversen L, Deleuran M, et al. Interleukin 13 suppresses cytokine production and stimulates the production of 15-HETE in PBMC. A comparison between IL-4 and IL-13. *Cytokine* 1995;7:319-24.
 50. Deleuran B, Iversen L, Kristensen M, et al. Interleukin-8 secretion and 15-lipoxygenase activity in rheumatoid arthritis: in vitro anti-inflammatory effects by interleukin-4 and interleukin-10, but not by interleukin-1 receptor antagonist protein. *Br J Rheumatol* 1994;33:520-5.
 51. Alaeddine N, Di Battista JA, Pelletier JP, Kiansa K, Cloutier JM, Martel-Pelletier J. Inhibition of tumor necrosis factor alpha-induced prostaglandin E₂ production by the antiinflammatory cytokines interleukin-4, interleukin-10, and interleukin-13 in osteoarthritic synovial fibroblasts: distinct targeting in the signaling pathways. *Arthritis Rheum* 1999;42:710-8.
 52. Hart PH, Hunt EK, Bonder CS, Watson CJ, Finlay-Jones JJ. Regulation of surface and soluble TNF receptor expression on human monocytes and synovial fluid macrophages by IL-4 and IL-10. *J Immunol* 1996;157:3672-80.